{"entity":{"id":"immutep","kind":"company","name":"Immutep","aka":["Immutep S.A.S.","Immutep Limited","Prima BioMed"],"tldr":"Immutep is an Australian-French company built on the immune checkpoint LAG-3, whose soluble LAG-3 protein eftilagimod alpha is in the phase 3 TACTI-004 trial with pembrolizumab and chemotherapy in first-line non-small-cell lung cancer.","summary":"Immutep, listed in Sydney and on Nasdaq and with research in Paris, develops therapies around LAG-3, a checkpoint discovered by its scientific founder. Its lead, eftilagimod alpha (efti), is a soluble LAG-3 protein that activates antigen-presenting cells through MHC class II rather than blocking a checkpoint, and is combined with PD-1 antibodies and chemotherapy; after phase 2 results in lung and head and neck cancer it began the phase 3 TACTI-004 trial in first-line non-small-cell lung cancer in 2025. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.immutep.com"},{"label":"ClinicalTrials.gov: trials led by Immutep","url":"https://clinicaltrials.gov/search?lead=Immutep"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Immutep"}],"tags":["ctgov-sponsor"],"related":[],"cancers":["nsclc","head-and-neck"],"sections":["immunotherapy"],"technologies":[],"targets":["lag3"],"drugs":["pembrolizumab"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Sydney","country":"AU","companyType":"biotech","website":"https://www.immutep.com","stage":"public","investors":[],"funding":[]},"route":"/companies/immutep/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"target":[{"id":"lag3","kind":"target","name":"LAG-3","route":"/targets/lag3/"}],"drug":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"}]}}